search
Back to results

A Study to Investigate the PK and Safety of CKD-393

Primary Purpose

Type II Diabetes

Status
Completed
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
CKD-393 formulation I
CKD-393 formulation II
D501, D759, H053
Sponsored by
Chong Kun Dang Pharmaceutical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type II Diabetes focused on measuring CKD-393, Type II Diabetes

Eligibility Criteria

19 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

[Inclusion Criteria]

  1. Between 19 aged and 50 aged healthy adult
  2. Body weight more than 55kg for male, more than 50kg for female
  3. Body Mass Index over 18.5kg/m2 and under 27.0kg/m2
  4. if female, the subject must satisfy more than one of the following:

    • subject who have reached menopause (no natural menstruation for at least 2 years.)
    • subject who is surgically infertile(hysterectomy or bilateral salpingo-oophorectomy, tubal ligation, or in infertile state under other method)

[Exclusion Criteria]

  1. Subject who is currently with or have diagnosed with clinically significant hepatobiliary(severe hepatopathy, etc.), kidney(severe nephropathy, etc.), neurological, immunologic, respiratory, urinary, gastrointestinal endocrinological(diabetic ketoacidosis, diabetic coma, etc.), hematological, oncological, cardiovascular(heart failure, etc.) or metal illness
  2. Subject with one of the following laboratory test results

    • AST, ALT > UNLx1.5
    • eGRF < 60 ml/min/1.73 m2 (MDRD formula)
    • immuno-serology test results in positive
    • Systolic blood pressure > 150mmHg or <90mmHg, Diastolic blood pressure >100mmHg or <50mmHg
  3. Subject who has history of the following and the history may affect safety of the subject or result of this study

    • History of any prescription drug or herbal medicine within 14 days before first administration investigational products
    • History of any non-prescription drug including health food, vitamin within 7 days before first administration investigational products
    • History of drug-metabolizing induction/inhibition enzyme such as barbital

Sites / Locations

  • Severance Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Group 1

Group 2

Group 3

Group 4

Group 5

Group 6

Arm Description

Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II

Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053

Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I

Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I

Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II

Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053

Outcomes

Primary Outcome Measures

Cmax
Maximum concentration of drug in plasma
AUClast
Area under the plasma drug concentration-time curve to last concentration

Secondary Outcome Measures

AUCinf
Area under the plasma drug concentration-time curve from 0 to infinity
Tmax
Time to maximum plasma concentration
t1/2
Terminal elimination half-life
Vd/F
Apparent Volume of Distribution
CL/F
Apparent Clearance

Full Information

First Posted
February 22, 2021
Last Updated
July 29, 2021
Sponsor
Chong Kun Dang Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT04768673
Brief Title
A Study to Investigate the PK and Safety of CKD-393
Official Title
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-393 and Co-administration of CKD-501, D759 and H053 Under Fed Condition in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
February 2021
Overall Recruitment Status
Completed
Study Start Date
March 26, 2021 (Actual)
Primary Completion Date
April 22, 2021 (Actual)
Study Completion Date
April 27, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chong Kun Dang Pharmaceutical

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393
Detailed Description
A randomized, open-label, single-dose, two-way crossover clinical trial to investigate the pharmacokinetics and safety after oral administration of CKD-393 and co-administration of CKD-501, D759 and H053 under fed condition in healthy adults

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type II Diabetes
Keywords
CKD-393, Type II Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation I / Period 3: CKD-393 Formulation II
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Period 1: CKD-393 Formulation I / Period 2: CKD-393 Formulation II / Period 3: CKD-501, D759, H053
Arm Title
Group 3
Arm Type
Experimental
Arm Description
Period 1: CKD-393 Formulation II / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation I
Arm Title
Group 4
Arm Type
Experimental
Arm Description
Period 1: CKD-501, D759, H053 / Period 2: CKD-393 Formulation II / Period 3: CKD-393 Formulation I
Arm Title
Group 5
Arm Type
Experimental
Arm Description
Period 1: CKD-393 Formulation I / Period 2: CKD-501, D759, H053 / Period 3: CKD-393 Formulation II
Arm Title
Group 6
Arm Type
Experimental
Arm Description
Period 1: CKD-393 Formulation II / Period 2: CKD-393 Formulation I / Period 3: CKD-501, D759, H053
Intervention Type
Drug
Intervention Name(s)
CKD-393 formulation I
Intervention Description
single, oral administration of 2 tablets under fed condition
Intervention Type
Drug
Intervention Name(s)
CKD-393 formulation II
Intervention Description
single, oral administration of 2 tablets under fed condition
Intervention Type
Drug
Intervention Name(s)
D501, D759, H053
Intervention Description
single, oral administration of 1 D501, 1 D759 and 2 H053 under fed condition
Primary Outcome Measure Information:
Title
Cmax
Description
Maximum concentration of drug in plasma
Time Frame
0 h (hours), 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Title
AUClast
Description
Area under the plasma drug concentration-time curve to last concentration
Time Frame
0 h (hours), 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Secondary Outcome Measure Information:
Title
AUCinf
Description
Area under the plasma drug concentration-time curve from 0 to infinity
Time Frame
0 h (hours), 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Title
Tmax
Description
Time to maximum plasma concentration
Time Frame
0 h (hours)h, 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Title
t1/2
Description
Terminal elimination half-life
Time Frame
0 h (hours), 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Title
Vd/F
Description
Apparent Volume of Distribution
Time Frame
0 h (hours), 0.25 h (hours)h, 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h
Title
CL/F
Description
Apparent Clearance
Time Frame
0 h (hours), 0.25 h (hours), 0.5h, 0.75h, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 24h, 32h, 48h

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
[Inclusion Criteria] Between 19 aged and 50 aged healthy adult Body weight more than 55kg for male, more than 50kg for female Body Mass Index over 18.5kg/m2 and under 27.0kg/m2 if female, the subject must satisfy more than one of the following: subject who have reached menopause (no natural menstruation for at least 2 years.) subject who is surgically infertile(hysterectomy or bilateral salpingo-oophorectomy, tubal ligation, or in infertile state under other method) [Exclusion Criteria] Subject who is currently with or have diagnosed with clinically significant hepatobiliary(severe hepatopathy, etc.), kidney(severe nephropathy, etc.), neurological, immunologic, respiratory, urinary, gastrointestinal endocrinological(diabetic ketoacidosis, diabetic coma, etc.), hematological, oncological, cardiovascular(heart failure, etc.) or metal illness Subject with one of the following laboratory test results AST, ALT > UNLx1.5 eGRF < 60 ml/min/1.73 m2 (MDRD formula) immuno-serology test results in positive Systolic blood pressure > 150mmHg or <90mmHg, Diastolic blood pressure >100mmHg or <50mmHg Subject who has history of the following and the history may affect safety of the subject or result of this study History of any prescription drug or herbal medicine within 14 days before first administration investigational products History of any non-prescription drug including health food, vitamin within 7 days before first administration investigational products History of drug-metabolizing induction/inhibition enzyme such as barbital
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Min Soo Park, MD, Ph.D
Organizational Affiliation
Severance Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Severance Hospital
City
Seoul
State/Province
Seodaemun-gu,
ZIP/Postal Code
03722
Country
Korea, Republic of

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Investigate the PK and Safety of CKD-393

We'll reach out to this number within 24 hrs